Expression of EGFR in Non-small Cell Lung Cancer and its Effects on Survival.
10.4046/trd.1997.44.6.1285
- Author:
Hak Ryul KIM
1
;
Eun Taik JEONG
Author Information
1. Department of Internal Medicine Wonkwang University College of Medicine, Iksan, Korea.
- Publication Type:Original Article
- Keywords:
EGFR;
Survival;
Lung cancer
- MeSH:
Adenocarcinoma;
Carcinogenesis;
Carcinoma, Non-Small-Cell Lung*;
Epidermal Growth Factor;
G1 Phase;
Humans;
Lung Neoplasms;
Oncogenes;
Signal Transduction;
Survival Rate
- From:Tuberculosis and Respiratory Diseases
1997;44(6):1285-1295
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: EGFR is one of the initial step in signal transduction pathway about multistep carcinogenesis. It is homologous to oncogene erbB-2 and is the receptor for EGF and TGF alpha. EGFR has important role in the growth and differentiation of tumor cells. So, EGFR in non-small cell lung cancer was examined to search for possible evidence as clinical prognostic factor. METHODS: To investigate the role of EGFR in lung cancer, the author performed immunohistochemical stain of EGFR on 57 resected primary non-small cell lung cancer specimens. And the author analyzed the correlation between EGFR expression, clinical parameters, S and G1 phase fraction and survival. RESULTS: 1) EGFR were detected in 56% of total 57 patients (according to histologic type, squamous cancer 50%, adenocarcinoma 63%, large cell cancer 75%) (according to TNM stage, stage I 64%, stage II 38%, stage III 55%) (according to cellular differentiation, well 50%, moderately 52%, poorly 65%). All differences were insignificant. 2) Using the flow cytometric analysis, mean S-phase fraction of EGFR (+) and (-) group were 22.3(+/-10.5)%. 18.0(+/-10.9)% (p>0.05), mean G1-phase fraction of EGFR (+) and (-) group were 68.4(+/-11.6)%, 71.1(+/-12.8)%, (p>0.05) 3) Two-year survival rate of EGFR (+) and (-) group were 53%, 84%, median survival time of EGFR (+) and (-) group were 26, 53 months. (p<0.05, Kaplan-Meier, generalized Wilcox) CONCLUISON: EGFR immunostaining may be a simple and useful method for survival prediction in non-small cell lung cancer.
